Drug Substance Capacity: 22,300 L capacity in operation; 90,500 L capacity is in planning

Drug Product Capacity: a vial fill finish line (liquid/powder) with 10 million/ year capacity; a prefilled syringe line with 10 million/year capacity

Filling line for 90,000L  Drug Substance is in planning

Media Production Capacity: 200 tons/year medium powder production capacity

ADC Production Capacity: have 10 ~ 100L glass reactors, 2×50L and 2×200L stainless steel reactors. 2×500L stainless steel reactors are in planning

Pilot Production (Drug Substance): 2×200L GMP production line, 1×500L GMP production line, 2×200L Non-GMP production line

Commercial production (Drug Substance): 3× 2,000L single use production line, 3×5,000 L stainless steel production line

Commercial production (Drug Product): lyophilization production line, vial filling production line, prefilled syringe production line

Medium production line: Zencore has a cGMP & ISO13485 Please medium dry powder production line, the manufacturing capacity is from 1kg to 1200 kg, and has 200 tons/year media production capacity, which can support media production from preclinical to clinical stage. 

ADC production line: The pilot production lines for drug substance ：2×10L, 2×20L, 2×50L, 2×100L meets cGMP requirements. The commercial drug substance manufacturing has 2×200L production lines that meets cGMP requirements, and another 2×500L production lines that is in preparation; It has pilot-scale drug product vial filling and 5m2 lyophilization production line that meet the requirements of cGMP. And commercial preparations of vial filling and 20m² lyophilization production line.

Six major R&D and manufacturing facilities are located at Zhoupu Medical Valley, Lin-gang Life Blue Bay in Shanghai, China, and Maryland, USA (within the FDA, NIH and NIST regions).

Zencore provides integrated services from preclinical research to commercial production for domestic and foreign pharmaceutical companies, boosting and accelerating the global bio-pharmaceutical R&D and industrialization process.

The company has a wide range of R&D capabilities, covering pharmaceutical evaluation, cell line development, upstream and downstream process development, analytical method development, and medium formulation development in the bio-pharmaceutical industry.

Core business  cell line development and media customization have a strong competitive advantage in the industry. Collaborate with leading enterprises in media industry to expand business and capacity.

With strong production capacity, the total production capacity will reach 22,300L by the end of 2022. And an additional 90,500L planned in the future.

Versatile drug product lines, Aseptic Vial Filling, Lyophilization, Prefilled Syringe can be performed.